From renewed FDA scrutiny to sharp criticism from segments of organized medicine, and even debates spilling into mainstream media, compounded medications have become the focus of a growing national conversation. At first glance, the issue is framed as one of safety. But as with many things in medicine, the reality is more nuanced. And now, with Colorado Senate Bill 26-066, that nuance is at risk of being lost in a wave of well-intentioned but potentially harmful regulation.
This moment deserves careful attention, not just from physicians and pharmacists, but from patients whose care may be directly affected.
What Compounding Really Is
Compounded medications are not experimental or fringe. They are customized prescriptions, created by licensed pharmacists based on a physician’s order to meet the specific needs of an individual patient.
This might mean:
- Adjusting the dose
- Removing dyes or allergens
- Changing the delivery method (cream, lozenge, liquid)
- Creating access when a drug is unavailable
This is not a loophole in medicine. It is, in fact, its original form. For centuries, the apothecary, today’s compounding pharmacist, was central to healthcare. Only in the mid-20th century did mass pharmaceutical manufacturing begin to dominate, driven by efficiency, scalability, and the economics of drug development, not by inherent safety superiority.
Today, compounded medications represent less than 1% of prescriptions, yet they are now the focus of outsized scrutiny.
The Current Narrative – Safety or Something Else?
The U.S. Food and Drug Administration has long acknowledged that compounding is legal and appropriate when performed by licensed pharmacists for specific patients using approved ingredients. State pharmacy boards, such as in Colorado, provide oversight and enforce safety standards comparable in many ways to federal expectations.
Yes, there have been isolated adverse events in the history of compounding. Those events rightly prompted improvements in oversight. But they do not define the entire field. So why the increasing pressure?
To understand that, we need to look at what compounding actually competes with.
The Economic Undercurrent
Compounded medications, particularly bioidentical hormones and more recently GLP-1 therapies, have begun to fill gaps that standardized pharmaceutical products cannot always address.
Bioidentical hormones, for example, are chemically identical to the body’s own hormones. They cannot be patented. And that matters.
Because in modern medicine, large-scale research, marketing, and distribution depend on patent protection. Without it, there is little financial incentive for pharmaceutical companies to invest in large trials or promotion.
So instead, companies often develop molecules that are “close enough” biologically, but different enough to be patented and marketed. This is not inherently wrong, it is how the system works. But it does create tension when non-patentable, customizable therapies begin to gain traction.
Enter Colorado SB 26-066
Now we arrive at the present moment.
Colorado Senate Bill 26-066 is being introduced under the banner of improving safety, specifically targeting concerns about counterfeit drugs and misuse. On the surface, that sounds reasonable.
But the practical implications tell a different story.
What the bill actually does:
- Imposes manufacturing-style regulations on compounding pharmacies
- Adds documentation and inspection requirements often outside a pharmacy’s control
- Specifically impacts access to GLP-1 medications, even when prescribed appropriately
Rather than targeting illegal online sellers or counterfeit supply chains, the bill places additional burdens on licensed, regulated pharmacies already operating within the law.
The likely result? Fewer pharmacies able to provide compounded medications, and fewer options for patients.
Why This Matters Clinically
Healthcare is not one-size-fits-all. Compounding exists because real patients don’t fit into standardized boxes.
Patients rely on compounded medications when:
- A drug is in shortage or unavailable
- A child needs a non-standard dose or liquid formulation
- A patient cannot tolerate fillers, dyes, or additives
- Standard therapies fail – whether in menopause, thyroid disease, dermatology, or chronic illness
And increasingly compounded is required when access to medications like GLP-1s is limited or requires individualized dosing. When compounding is restricted, patients are not simply redirected to a “safer” alternative. In many cases, there is no alternative.
A Familiar Pattern
One of the most common criticisms of compounded therapies is the lack of large, randomized controlled trials. That criticism deserves respect, but also context.
Most large trials are funded by pharmaceutical companies. That is how modern drug development works. But it also means that non-patentable therapies are far less likely to be studied at scale, regardless of their clinical utility.
We have seen before what happens when we rely too heavily on a single system of evidence and oversight. The case of Vioxx remains a sobering example – where both corporate interests and regulatory bodies failed to fully recognize or act on risk signals until significant harm had occurred.
The lesson is not that pharmaceutical companies are bad. They are essential. The lesson is that no single system is infallible.
Standardization vs Personalization
At its core, this debate is not about safety alone. It is about control. Do we move toward a system where all care must fit standardized, industrial frameworks? Or do we preserve a system where physicians and pharmacists retain the ability to individualize care?
Compounding represents the latter. And SB 26-066, despite its stated intentions, risks shifting the balance toward the former.
What Starts in Colorado Doesn’t Stay in Colorado
This is not just a local issue. Legislation like SB 26-066 often becomes a template for other states. What happens here could influence access to compounded medications nationwide.
This is how healthcare policy evolves – quietly, incrementally, and often without patients realizing what is being lost until it is gone.
What You Can Do
This is one of those moments where engagement matters. If you believe that:
- Patients should retain access to individualized therapies
- Physicians and pharmacists should be able to exercise clinical judgment
- Regulation should target bad actors—not lawful providers
Then your voice is needed.
TAKE ACTION –> Visit the advocacy website associated with SB 26-066
Read the Op-Ed explaining its impact. Contact your state legislators. Petition your representatives to oppose the bill.
Lawmakers need to hear from patients and clinicians, not just institutions.
The Bottom Line
Compounding pharmacies are not a relic of the past. They are a living, necessary part of modern medicine.
Pharmaceutical companies are not the enemy. They are one of medicine’s greatest strengths.
But when legislation threatens to eliminate one side of that balance, we risk losing something essential. Not just a type of pharmacy. Not just a category of medication. But the ability to treat patients as individuals.
At the end of the day, the question is simple: Who decides what is best for the patient?
If SB 26-066 moves forward unchecked, that decision may drift further away from the exam room and closer to systems that were never designed to accommodate the complexity of real human care.
For now, there is still time to speak up.
Author
Scott Rollins, MD, is Board Certified with the American Board of Family Practice and the American Board of Anti-Aging and Regenerative Medicine. He specializes in bioidentical hormone replacement for men and women, thyroid and adrenal disorders, fibromyalgia and other complex medical conditions. He is founder and medical director of the Integrative Medicine Center of Western Colorado (www.imcwc.com) and Bellezza Laser Aesthetics (www.bellezzalaser.com). Call (970) 245-6911 for an appointment or more information.
